Bio-Rad Laboratories, Inc.
BIO
$238.68
-$2.34-0.97%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 64.00M | -715.80M | 653.17M | -2.17B | 383.90M |
| Total Depreciation and Amortization | 38.10M | 39.20M | 38.90M | 36.40M | 37.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.80M | 1.02B | -749.21M | 2.91B | -405.20M |
| Change in Net Operating Assets | 43.60M | -216.00M | 220.70M | -679.50M | 54.00M |
| Cash from Operations | 129.90M | 124.20M | 163.56M | 97.65M | 69.80M |
| Capital Expenditure | -34.40M | -42.91M | -40.23M | -42.28M | -40.20M |
| Sale of Property, Plant, and Equipment | -- | -49.00K | 57.00K | 66.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.30M | 12.42M | -15.46M | 11.29M | -2.90M |
| Cash from Investing | 2.90M | -30.54M | -55.64M | -30.93M | -43.10M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.00K | -41.00K | -123.00K | -118.00K | -200.00K |
| Issuance of Common Stock | 4.30M | 3.91M | 5.10M | 4.68M | 5.50M |
| Repurchase of Common Stock | -101.90M | -134.00K | -100.97M | -101.15M | -4.70M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -29.98M | 0.00 | 0.00 | -600.00K |
| Cash from Financing | -97.70M | -26.25M | -95.99M | -96.59M | 0.00 |
| Foreign Exchange rate Adjustments | -1.80M | 10.22M | -7.52M | 3.83M | 2.70M |
| Miscellaneous Cash Flow Adjustments | -- | -48.00K | 48.00K | -- | -- |
| Net Change in Cash | 33.30M | 77.58M | 4.47M | -26.04M | 29.40M |